Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

Rhea-AI Summary

Compass Therapeutics, Inc. (Nasdaq: CMPX) will host a webinar on May 4, 2022, at 8:00 a.m. ET to discuss clinical data from its ongoing Phase 2 trial of CTX-009. A Key Opinion Leader will join the management for this review. The company focuses on developing proprietary antibody-based therapeutics targeting cancer through a unique approach addressing angiogenesis and immune response. The upcoming session aims to provide insights into trial results, with a replay available for six months on the company's website.

Positive

• Ongoing Phase 2 trial of CTX-009 indicates progression in clinical development.
• Webinar aims to discuss key clinical data, engaging expert opinions.

Negative

• None.

Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET

Key Opinion Leader to Participate

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion.

Webinar Details:
Date:		May 04, 2022
Time:		8:00 a.m. ET
Webcast:		Registration Link
Replay availability:		A replay will be available on the Compass website for 6 months.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
Vered Bisker-Leib, President & Chief Operating Officer
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099

FAQ

What is the purpose of Compass Therapeutics' Phase 2 trial for CTX-009?

The Phase 2 trial aims to assess the efficacy and safety of CTX-009 in treating cancer.

When is the webinar to discuss CTX-009 clinical data scheduled?

The webinar is scheduled for May 4, 2022, at 8:00 a.m. ET.

Who will be participating in the Compass Therapeutics webinar?

A Key Opinion Leader will join the management for the discussion during the webinar.

Where can I find the replay of the CTX-009 webinar?

The replay will be available on the Compass Therapeutics website for six months after the event.

What type of therapeutics is Compass Therapeutics developing?

Compass Therapeutics is developing proprietary antibody-based therapeutics focused on cancer treatment.